Neurobo Pharmaceuticals Inc (NRBO)

4.7500 -0.0200 (-0.42%)
Real-time Cboe USD Disclaimer

Neurobo Pharmaceuticals Inc Company Profile

Equity Type
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Contact Information
Cambridge,02138 United States
857 702 9600
Top Executives
Roy Lester Freeman 71 0000 Chairman of Scientific Advisory Board
Andrew I. Koven 66 2021 Independent Chairman of the Board
D. Gordon Strickland 77 2022 Independent Director
Michael H. Salsbury 74 2019 Independent Director
Jason L. Groves 53 2019 Independent Director
Hyung-Heon Kim 49 2021 CEO, President, Principal Executive & Director
Caroline M. Apovian 0 0000 Member of Scientific Advisory Board
Leigh Perreault 0 0000 Member of Scientific Advisory Board
Mark A. Glickman 58 2023 Independent Director
James Patrick Tursi 59 2023 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.